Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · July 09, 2021

Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD

Journal of Crohn's & Colitis


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Crohn's & Colitis
Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts
J Crohns Colitis 2021 Jun 05;[EPub Ahead of Print], LAAP Derikx, HW Dolby, N Plevris, L Lucaciu, CS Rees, M Lyons, SI Siakavellas, N Constantine-Cooke, P Jenkinson, S Su, C O'Hare, L Kirckpatrick, LM Merchant, C Noble, ID Arnott, GR Jones, CW Lees

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading